A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

19 Nov 2020 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped:Regeneron has discontinued further clinical development of REGN5069, an antibody to GFR alpha 3,which was previously being studied in osteoarthritis pain of the knee.
09 Mar 2020 Planned End Date changed from 1 Jul 2021 to 3 Feb 2021.
09 Mar 2020 Planned primary completion date changed from 24 Sep 2020 to 29 Apr 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com